Artelo Biosciences, Inc.

NasdaqCM ARTL

Artelo Biosciences, Inc. Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending September 30, 2023

Artelo Biosciences, Inc. Free Cash Flow Per Share is NA for the Trailing 12 Months (TTM) ending September 30, 2023. Free cash flow per share is the free cash flow generated per share. Indicates investment potential based on cash flow generation.

Artelo Biosciences, Inc. Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -2.90, a -299.39% change year over year.
Artelo Biosciences, Inc. Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending August 31, 2021 was USD -0.73, a 54.42% change year over year.
Artelo Biosciences, Inc. Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending August 31, 2020 was USD -1.59, a 65.25% change year over year.
Artelo Biosciences, Inc. Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending August 31, 2019 was USD -4.59, a -45.96% change year over year.

Key data

Date	Free Cash Flow Per Share	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)

NasdaqCM: ARTL

Artelo Biosciences, Inc.

CEO	Mr. Gregory D. Gorgas M.B.A.
IPO Date	June 21, 2019
Location	United States
Headquarters	505 Lomas Santa Fe
Employees	5
Sector	Healthcare
Industries Biotechnology 3D Printing Clinical Trials Cosmetics Mental Health Pet Food Pharmaceuticals Vaccines

Description

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences, Inc. has research collaboration with Trinity College Dublin to investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

Key trends

Past 5 years